Cocrystal Pharma, Inc. (COCP)
NASDAQ: COCP · Real-Time Price · USD
1.420
+0.010 (0.71%)
Apr 4, 2025, 4:00 PM EDT - Market closed

Cocrystal Pharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020 2015 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Net Income
--17.98-38.84-14.19-9.65
Upgrade
Depreciation & Amortization
-0.190.190.380.34
Upgrade
Asset Writedown & Restructuring Costs
--19.09--
Upgrade
Stock-Based Compensation
-0.80.860.720.66
Upgrade
Other Operating Activities
--0.01-0.02-0.24-0.12
Upgrade
Change in Accounts Receivable
---0.560.09
Upgrade
Change in Accounts Payable
-2.05-0.320.22-0.92
Upgrade
Change in Other Net Operating Assets
-0.47-1.68-0.17-0.23
Upgrade
Operating Cash Flow
--14.67-21.44-12.72-9.83
Upgrade
Capital Expenditures
--0.12-0.07-0.05-0.24
Upgrade
Investing Cash Flow
--0.12-0.07-0.05-0.24
Upgrade
Long-Term Debt Repaid
--0.01-0.03-0.04-0.12
Upgrade
Net Debt Issued (Repaid)
--0.01-0.03-0.04-0.12
Upgrade
Issuance of Common Stock
-4-38.5135.78
Upgrade
Financing Cash Flow
-3.99-0.0338.4735.66
Upgrade
Net Cash Flow
--10.79-21.5425.725.59
Upgrade
Free Cash Flow
--14.78-21.51-12.77-10.07
Upgrade
Free Cash Flow Margin
-----500.00%
Upgrade
Free Cash Flow Per Share
--1.53-2.64-1.73-2.19
Upgrade
Levered Free Cash Flow
--10.01-13.12-7.28-6.25
Upgrade
Unlevered Free Cash Flow
--10.01-13.12-7.28-6.24
Upgrade
Change in Net Working Capital
-0.12-2.342.75-0.561.01
Upgrade
Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q